Trial Outcomes & Findings for Testing the Effectiveness of WW Clinic GLP1 (NCT NCT06034457)

Results Overview

Effect of WW GLP1 behavioral program + WW Clinic (formerly known as Sequence) on absolute change of weight loss at 24 weeks.

Recruitment status

COMPLETED

Target enrollment

180 participants

Primary outcome timeframe

0 to 24 weeks

Results posted on

2025-12-19

Participant Flow

Participant milestones

Participant milestones
Measure	Single Arm WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Overall Study STARTED	180
Overall Study COMPLETED	166
Overall Study NOT COMPLETED	14

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Testing the Effectiveness of WW Clinic GLP1

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Age, Continuous	44.11 years STANDARD_DEVIATION 10.41 • n=8 Participants
Sex/Gender, Customized Male	16 Participants n=8 Participants
Sex/Gender, Customized Female	164 Participants n=8 Participants
Sex/Gender, Customized Intersex	0 Participants n=8 Participants
Sex/Gender, Customized Prefer not to say	0 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	14 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	166 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	2 Participants n=8 Participants
Race (NIH/OMB) Asian	2 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=8 Participants
Race (NIH/OMB) Black or African American	20 Participants n=8 Participants
Race (NIH/OMB) White	146 Participants n=8 Participants
Race (NIH/OMB) More than one race	4 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	5 Participants n=8 Participants

PRIMARY outcome

Timeframe: 0 to 24 weeks

Effect of WW GLP1 behavioral program + WW Clinic (formerly known as Sequence) on absolute change of weight loss at 24 weeks.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Change in Weight in Pounds From Week 0 to Week 24	-27.41 pounds Standard Deviation 14.86

SECONDARY outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on weight loss and % reaching 5, 10, 15, 20 % body weight loss at 24 weeks.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Weight Loss Percentage Change From Week 0 to Week 24 Number of participants with >= 5% weight loss at 24 weeks	161 Participants
Weight Loss Percentage Change From Week 0 to Week 24 Number of participants with >= 10% weight loss at 24 weeks	121 Participants
Weight Loss Percentage Change From Week 0 to Week 24 Number of participants with >= 15% weight loss at 24 weeks	81 Participants
Weight Loss Percentage Change From Week 0 to Week 24 Number of participants with >= 20% weight loss at 24 weeks	20 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of blood pressure at 24 weeks

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Blood Pressure Changes (Systolic and Diastolic) in mmHg From Week 0 to Week 24 Change in diastolic blood pressure at 24 weeks	-5.66 mmHg Standard Deviation 13.29
Blood Pressure Changes (Systolic and Diastolic) in mmHg From Week 0 to Week 24 Change in systolic blood pressure at 24 weeks	-11.17 mmHg Standard Deviation 14.96

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Quality of Life (QOL) scores using "Impact of Weight on Quality of Life-Lite Scale" Scale Name + Description of scale: "Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Is a validated, 31-item, self-report measure of obesity-specific quality of life in adults. There are five domains include physical function, self-esteem, sexual life, public distress and work. Scale Ranges (min, max): 0-100 Description of scoring: Higher scores represent lower quality of life (i.e., greater impact of obesity on quality of life). Lower scores represent a better quality of life (i.e., less impact of obesity). A negative mean change indicates improvement in quality of life.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Change in Quality of Life Scores From Week 0 to Week 24 Physical Function	-20.13 score on a scale Standard Deviation 17.79
Change in Quality of Life Scores From Week 0 to Week 24 Self-Esteem	-27.98 score on a scale Standard Deviation 22.5
Change in Quality of Life Scores From Week 0 to Week 24 Sexual Life	-18.27 score on a scale Standard Deviation 23.1
Change in Quality of Life Scores From Week 0 to Week 24 Public Distress	-11.44 score on a scale Standard Deviation 17.99
Change in Quality of Life Scores From Week 0 to Week 24 Work	-12.08 score on a scale Standard Deviation 19.81
Change in Quality of Life Scores From Week 0 to Week 24 Total Score	-19.19 score on a scale Standard Deviation 13.42

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Well-being at 24 weeks using "WHO Well-Being Index 5" Scale Name + Description of scale: "Well-being Index 5 (WHO-5)" is a 5-item questionnaire that assesses subjective well-being through five statements about feeling cheerful, calm, active, interested and rested over the past two weeks. Scale Ranges (min, max) 0-25 Description of scoring: Lower scores indicate worse overall well-being, higher scores indicate better overall well-being. A positive mean change indicates improvement in well-being.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Well-being Scores From Week 0 to Week 24	2.92 score on a scale Standard Deviation 3.98

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Disordered Eating at 24 weeks using "Eating Disorder Examination-Questionnaire" Scale Name + Description of scale: "Eating Disorder Examination-Questionnaire (EDE-Q)" is a 28-item self-report questionnaire, adapted from the semi-structured interview, the Eating Disorder Examination (EDE). The questionnaire is designed to assess the range, frequency and severity of behaviors associated with a diagnosis of an eating disorder. Scale Ranges (min, max): 0-6 Description of scoring: Lower scores indicate less problematic eating disordered behaviors and cognitions and higher scores indicate more problematic eating disordered behaviors and cognitions. A positive mean change indicates an increase in eating disordered symptoms. A negative mean change could indicate a decrease in eating disorder symptoms.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Disordered Eating Scores From Week 0 to Week 24 Eating Concerns Score	-0.75 score on a scale Standard Deviation 1.28
Changes in Disordered Eating Scores From Week 0 to Week 24 Restraint Score	0.09 score on a scale Standard Deviation 1.74
Changes in Disordered Eating Scores From Week 0 to Week 24 Shape Concern Score	-1.04 score on a scale Standard Deviation 1.07
Changes in Disordered Eating Scores From Week 0 to Week 24 Weight Concern Score	-0.76 score on a scale Standard Deviation 0.8
Changes in Disordered Eating Scores From Week 0 to Week 24 Global Score	-0.61 score on a scale Standard Deviation 0.95

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Strength Training Behavior at 24 weeks using the "Strength Training Behavior Scale" Scale Name + Description of scale: "Stage of Change for Strength Training" Strength training is defined as all activities that serve to enhance muscle strength and endurance (free weights, body weight exercises, etc.) Regular resistance training is described as engaging in these activities at least two times per week. Scale Ranges (min, max): 0-7 Description of scoring: Lower scores indicate less days strength training. Higher scores equal more days of strength training. A positive mean change indicates an increase in number of days of strength training.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Strength Training Scores From Week 0 to Week 24	0.48 score on a scale Standard Deviation 1.37

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Stress at 24 weeks using the "Perceived Stress Scale" Scale Name + Description of scale: "Perceived Stress Scale, PSS-10" is a self-report scale that asks about feelings and thoughts related to stressful things during the last month. Scale Ranges (min, max): 10-50 Description of scoring: Higher scores indicate more perceived stress and lower scores indicate less perceived stress. A negative mean change indicates improvement in perceived stress.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Stress Scores From Week 0 to Week 24	-2.66 score on a scale Standard Deviation 6.51

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Emotional Eating scores using the "Palatable Eating Motives Scale-Coping Subscale" Scale Name + Description of scale: "Palatable Eating Motives Scale - Coping Subscale (PEMs-Coping)" is a four-item coping subscale of the PEMs self-report that measures eating behavior as a method of coping with problems and negative feelings. Scale Ranges (min, max): 4-20 Description of scoring: Lower scores indicate lower frequency of eating as a method of coping with problems and negative feelings. Higher scores indicate higher frequency of eating as a method of coping with problems and negative feelings. A negative mean score indicates a decrease in using eating to cope with problems and negative feelings.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Emotional Eating Scores From Week 0 to Week 24	-3.99 score on a scale Standard Deviation 4.79

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Unhealthy Habits scores using "Self-Reported Behavioral Automaticity Index" Scale Name + Description of scale: "Self-Reported Behavioral Automaticity Index (SRBAI)-Unhealthy Habits Subscale" is a self-report measure to assess how automatic or habitual certain behaviors are, often used to understand unhealthy habits. Unhealthy habits included are eating sugary foods, fried foods and drinking sugary drinks. Scale Ranges (min, max): 1-7 Description of scoring: Lower scores indicate less automatic or habitual unhealthy habits. Higher scores indicate more automatic or habitual unhealthy habits. A negative mean change indicates a decrease in automatic or habitual unhealthy behaviors.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in UnHealthy Habits Strength Scores From Week 0 to Week 24 Sugary Foods	-1.64 score on a scale Standard Deviation 1.86
Changes in UnHealthy Habits Strength Scores From Week 0 to Week 24 Fried Foods	-1.13 score on a scale Standard Deviation 1.81
Changes in UnHealthy Habits Strength Scores From Week 0 to Week 24 Drinking	-0.83 score on a scale Standard Deviation 1.66

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Habit Strength scores using the "Self-Reported Behavioral Automaticity Index for Healthy Habits" Scale Name + Description of scale: "Self-Reported Behavioral Automaticity Index (SRBAI) Healthy Habits Subscale" is a self-report measure to assess how automatic or habitual certain behaviors are, often used to understand healthy habits. Healthy habits included are portion control, food tracking, protein content, eating vegetables, weighing self, physical activity, positive self-talk after a setback, arranging kitchen so healthy foods are easy to access and meal planning. Scale Ranges (min, max): 1-7 Description of scoring: Lower scores indicate less automatic or habitual healthy habits. Higher scores indicate more automatic or habitual healthy habits. A positive mean change indicates an increase in automatic or habitual healthy behaviors.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Snacking	0.61 score on a scale Standard Deviation 1.81
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Portion	1.72 score on a scale Standard Deviation 1.68
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Tracking	0.55 score on a scale Standard Deviation 1.86
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Points	1.24 score on a scale Standard Deviation 1.82
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Vegetables	0.48 score on a scale Standard Deviation 1.4
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Weighing	1.29 score on a scale Standard Deviation 2.01
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Physically	1.02 score on a scale Standard Deviation 1.57
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Self-Talk	0.82 score on a scale Standard Deviation 1.74
Changes in Healthy Habits Strength Scores From Week 0 to Week 24 Healthy Food	0.97 score on a scale Standard Deviation 1.79

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Weight Bias Internalization scores using "Weight Bias Internalization Scale" Scale Name + Description of scale: "Weight Bias Internalization Scale, WBIS-2F" is a 13-item measure developed to assess weight related self-stigma. Scale Ranges (min, max): 13-91 Description of scoring: Lower scores indicate more weight related self-stigma, higher scores indicate less weight related self-stigma. A negative mean change indicates a decrease in weight related self-stigma.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Weight Bias Internalization Scores From Week 0 to Week 24	-7.12 score on a scale Standard Deviation 9.83

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Self-Compassion scores using the "Self-Compassion Scale" Scale Name + Description of scale: "Self-Compassion Scale" is a self-report questionnaire that asks how someone typically acts towards themselves in difficult times. Scale Ranges (min, max): 1-5 Description of scoring: Lower scores indicate that an individual might be more critical of themselves during difficult times. Higher scores might indicate someone who might be less critical on themselves during difficult times. A positive mean change indicates more self-compassion.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Self-Compassion Scores From Week 0 to Week 24	0.05 score on a scale Standard Deviation 0.32

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Number of Participants with GLP1 Side Effects from week 0 to week 24

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Complete Lack of Appetite	10 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Injection Site Reaction	7 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Hair Loss	4 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Nausea	146 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Other	67 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Constipation	54 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Diarrhea	41 Participants
Number of Participants With GLP1 Side Effects From Week 0 to Week 24 Abdominal Pain	13 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Restraint/Disinhibition scores using the "Three Factor Eating Questionnaire" Scale Name + Description of scale: "Three Factor Eating Questionnaires, TFEQ". Is a self-report scale that measures three dimensions of eating behavior: cognitive restraint, disinhibition and hunger. The first two factors were included. Scale Ranges (min, max): restraint 0-21, disinhibition 0-16 Description of scoring: Lower scores indicate less restraint. Higher scores indicate more restraint. A positive change indicates improvement in restraint. Lower scores indicate less disinhibition. Higher scores indicate more disinhibition. A negative mean change improvement in disinhibition.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Restraint/Disinhibition Scores From Week 0 to Week 24 Restraint Score	2.42 score on a scale Standard Deviation 4.03
Changes in Restraint/Disinhibition Scores From Week 0 to Week 24 Disinhibition Score	-3.72 score on a scale Standard Deviation 3.49

OTHER_PRE_SPECIFIED outcome

Timeframe: 0 to 24 weeks

Effect of WW + WW Clinic (formerly known as Sequence) on absolute change of Depression symptoms using the "Patient Health Questionnaire-8" Scale Name + Description of scale: "Patient Health Questionniare-8 item" is a self-report scale that rates depressive symptoms including questions about interest, enjoyment, sadness, sleep, appetite, energy, guilt, concentration. Scale Ranges (min, max): 0-24 Description of scoring: Lower scores indicate fewer depressive symptoms, higher scores indicate more depressive symptoms. A negative mean change indicates an improvement in depressive symptoms.

Outcome measures

Outcome measures
Measure	Single Arm n=180 Participants WW GLP-1 behavioral program program + Sequence medical weight management prescribed semaglutide or tirzepatide.
Changes in Depression Symptom Scores From Week 0 to Week 24	-2.99 score on a scale Standard Deviation 4.59

Adverse Events

Single Arm

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Leslie Heinberg, Vice Chair for Psychology, Department of Psychiatry and Psychology

Cleveland Clinic

Phone: 216 445-1986

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place